Advertisement

Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice

      Highlights

      • The 2015 NMOSD and 2018 MOG-ab diagnostic criteria must be used in LATAM patients.
      • The panel recommends to test AQP4-ab and MOG-ab using cell-based assay
      • A standardized MRI protocol should be applied at diagnosis and follow-up.
      • For exacerbations, early IV steroids or PLEX (no response to steroids) must be used
      • We recommend rituximab or mycophenolate use for long-term relapse prevention

      Abstract

      Background

      During the last two decades, neuromyelitis optica spectrum disorder (NMOSD) has undergone important changes, with new diagnostic markers and criteria, better recognition of clinical phenotypes, better disease prognosis and new therapeutic approaches. Consequently, management of NMOSD patients in Latin American (LATAM) has become more complex and challenging in clinical practice. In making these consensus recommendations, the aim was to review how the disease should be managed and treated among LATAM patients, in order to improve long-term outcomes in these populations.

      Methods

      A panel of LATAM neurologists who are experts in demyelinating diseases and dedicated to management and care of NMOSD patients gathered virtually during 2019 and 2020 to make consensus recommendations on management and treatment of NMOSD patients in LATAM. To achieve this consensus, the RAND/UCLA methodology for reaching formal consensus was used.

      Results

      The recommendations focused on diagnosis and differential diagnoses, disease prognosis, tailored treatment, identification of suboptimal treatment response and special circumstances management. They were based on published evidence and expert opinions.

      Conclusions

      The recommendations of these consensus guidelines seek to optimize management and specific treatment of NMOSD patients in LATAM

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Abboud H
        • Petrak A
        • Mealy M
        • et al.
        Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange.
        Mult. Scler. 2016; 22: 185-192
        • Alvarenga MP
        • Schimidt S
        • Alvarenga RP
        Epidemiology of neuromyelitis optica in Latin America.
        Mult. Scler. J. Exp. Transl. Clin. 2017; 32055217317730098
        • Amaral JM
        • Talim N
        • Kleinpaul R
        • Lana-Peixoto MA
        • Brazilian Committee for Treatment and Research in Multiple Sclerosis
        Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders.
        Mult. Scler. Relat. Disord. 2020; 41102045
        • Araki M
        • Matsuoka T
        • Miyamoto K
        • et al.
        Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.
        Neurology. 2014; 82: 1302-1306
        • Asseyer S
        • Schmidt F
        • Chien C
        • et al.
        Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders.
        Mult. Scler. J. Exp. Transl. Clin. 2018; 42055217318796684
        • Banerjee A
        • Ng J
        • Coleman J
        • Ospina JP
        • et al.
        Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment.
        Mult. Scler. Relat. Disord. 2019; 28 (Feb): 60-63
        • Bedi GS
        • Brown AD
        • Delgado SR
        • et al.
        Impact of rituximab on relapse rate and disability in neuromyelitis optica.
        Mult. Scler. 2011; 17: 1225-1230
        • Beekman J
        • Keisler A
        • Pedraza O
        • et al.
        Neuromyelitis optica spectrum disorder: patient experience and quality of life.
        Neurol. Neuroimmunol. Neuroinflamm. 2019; 6: e580
        • Bell BG
        • Spencer R
        • Avery AJ
        • Campbell SM
        Tools for measuring patient safety in primary care settings using the RAND/UCLA appropriateness method.
        BMC Fam. Pract. 2014; 15: 110
        • Bennett JL
        • de Seze J
        • Lana-Peixoto M
        • et al.
        Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography.
        Mult. Scler. 2015; 21 (May;): 678-688
        • Bergamaschi R
        • Tonietti S
        • Franciotta D
        • et al.
        Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations.
        Mult. Scler. 2004; 10: 2-4
        • Bichuetti DB
        • Lobato de Oliveira EM
        • Oliveira DM
        • et al.
        Neuromyelitis optica treatment: analysis of 36 patients.
        Arch. Neurol. 2010; 67: 1131-1136
        • Bichuetti DB
        • Perin MMM
        • Souza NA
        • Oliveira EML
        Treating neuromyelitis optica with azathioprine: 20-year clinical practice.
        Mult. Scler. 2019; 25 (Jul): 1150-1161
        • Birnbaum J
        • Atri NM
        • Baer AN
        • et al.
        Relationship between neuromyelitis optica spectrum disorder and Sjögren’s syndrome: central nervous system extraglandular disease or unrelated, co-occurring autoimmunity?.
        Arthritis Care Res. (Hoboken). 2017; 69 (Jul): 1069-1075https://doi.org/10.1002/acr.23107
        • Bonnan M
        • Cabre P.
        Plasma exchange in severe attacks of neuromyelitis optica.
        Mult. Scler. Int. 2012; 2012787630
        • Bonnan M
        • Valentino R
        • Debeugny S
        • Merle H
        • Ferge JL
        • Mehdaoui H
        • et al.
        Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders.
        J. Neurol. Neurosurg. Psychiatry. 2018; 89: 346-351
        • Borisow N
        • Hellwig K
        • Paul F
        Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies.
        EPMA J. 2018; 9 (Aug 10): 249-256
        • Bursztyn LLCD
        • De Lott LB
        • Petrou M
        • Cornblath WT
        Sensitivity of orbital magnetic resonance imaging in acute demyelinating optic neuritis.
        Can. J. Ophthalmol. 2019; 54 (Apr): 242-246
        • Carnero Contentti E
        • Daccach Marques V
        • Soto de Castillo I
        • et al.
        Short-segment transverse myelitis lesions in a cohort of Latin American patients with neuromyelitis optica spectrum disorders.
        Spinal Cord. 2018; 56: 949-954
        • Carnero Contentti E
        • Daccach Marques V
        • Soto de Castillo I
        • et al.
        Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: a cohort of Latin American patients.
        Mult. Scler. Relat. Disord. 2018; 19: 73-78
        • Carnero Contentti E
        • Daccach Marques V
        • Soto de Castillo I
        • et al.
        Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort.
        J. Neurol. 2020; 267: 1260-1268
        • Carnero Contentti E
        • De Virgiliis M
        • Hryb JP
        • et al.
        Aquaporin-4 serostatus and visual outcomes in clinically isolated acute optic neuritis.
        J. Neuroophthalmol. 2019; 39 (Jun;): 165-169
        • Carnero Contentti E
        • Giachello S
        • Correale J
        Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients [published online ahead of print, 2020 Jan 21].
        Mult. Scler. 2020; (1352458519898590)
        • Carnero Contentti E
        • Leguizamón F
        • Hryb JP
        • Celso J
        • Pace JL
        • Ferrari J
        • Knorre E
        • Perassolo MB
        Neuromyelitis optica: association with paroxysmal painful tonic spasms.
        Neurologia. 2016 Oct;; 31: 511-515
        • Carnero Contentti E
        • Marques VD
        • Soto de Castillo I
        • et al.
        Brain and spinal MRI features distinguishing MS from different AQP4 antibody serostatus NMOSD at disease onset in a cohort of Latin American patients.
        Mult. Scler. 2019; (May 241352458519849517)
        • Carnero Contentti E
        • Sotode Castillo I
        • Daccach Marques V
        • et al.
        Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients.
        Mult. Scler. Relat. Disord. 2018; 20: 109-114
        • Chen H
        • Qiu W
        • Zhang Q
        • Wang J
        • Shi Z
        • Liu J
        • et al.
        Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
        Eur. J. Neurol. 2017; 24: 219-226
        • Ciccarelli O
        • Cohen JA
        • Reingold SC
        • Weinshenker BG
        • International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
        Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders.
        Lancet Neurol. 2019; 18 (Feb;): 185-197
        • Ciron J
        • Audoin B
        • Bourre B
        • et al.
        Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders.
        Rev. Neurol. (Paris). 2018; 174 (Apr): 255-264
        • Cohen M.
        • Romero G.
        • Bas J.
        • et al.
        Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study.
        J. Neurol. Sci. 2017; 373: 335-338
        • Collongues N
        • Ayme-Dietrich E
        • Monassier L
        • de Seze J
        Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options.
        Drugs. 2019; 79 (Feb): 125-142
        • Collongues N
        • Brassat D
        • Maillart E
        • et al.
        Efficacy of rituximab in refractory neuromyelitis optica.
        Mult. Scler. 2016; 22: 955-959
        • Comi G.
        • Radaelli M.
        • Soelberg Sorensen P.
        Evolving concepts in the treatment of relapsing multiple sclerosis.
        Lancet. 2017; 389: 1347-1356
        • Cortese R
        • Magnollay L
        • Tur C
        • et al.
        Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD.
        Neurology. 2018; 90: e1183-e1190
        • Costanzi C
        • Matiello M
        • Lucchinetti CF
        • et al.
        Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
        Neurology. 2011; 77: 659-666
        • Cree BAC
        • Bennett JL
        • Kim HJ
        • et al.
        Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
        Lancet. 2019; 394 (Oct 12): 1352-1363
        • Cristiano E
        • Rojas JI
        • Alonso R
        • et al.
        Consensus recommendations on the management of multiple sclerosis patients in Argentina.
        J. Neurol. Sci. 2020; 409 (Feb 15)116609
        • Damato V
        • Evoli A
        • Iorio R
        Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
        JAMA Neurol. 2016; 73: 1342-1348
        • Delgado-García G
        • Méndez-Zurita VA
        • Bayliss L
        • Flores-Rivera J
        • Fleury A
        Neurocysticercosis: mimics and chameleons.
        Pract. Neurol. 2019; 19: 88-95
        • Delgado-García G.
        • Chávez Z.
        • Rivas-Alonso V.
        • Corona T.
        • Flores-Rivera J.
        Obstetric outcomes in a Mexican cohort of patients with AQP4-antibody seropositive neuromyelitis optica.
        Mult. Scler. Relat. Disord. 2018; 25: 268-270
        • Drulovic J
        • Martinovic V
        • Basuroski ID
        • Mesaros S
        • Mader S
        • Weinshenker B
        • Pekmezovic T
        Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia.
        Mult. Scler. Relat. Disord. 2019; 36 (Nov)101413
        • Elsone L
        • Kitley J
        • Luppe S
        • et al.
        Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicenter retrospective observational study from the UK.
        Mult. Scler. 2014; 20: 1533-1540
        • Flanagan EP
        • Weinshenker BG
        • Krecke KN
        • Lennon VA
        • Lucchinetti CF
        • McKeon A
        • et al.
        Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
        JAMA Neurol. 2015; 72: 81-87
        • Flanagan EP
        • Weinshenker BG.
        Neuromyelitis optica spectrum disorders.
        Curr. Neurol. Neurosci. Rep. 2014; 14 (Sep): 483
        • Flanagan EP.
        Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases.
        Continuum (Minneap Minn). 2019; 25: 815-844
        • Fragoso YD
        • Adoni T
        • Bichuetti DB
        • et al.
        Neuromyelitis optica and pregnancy.
        J. Neurol. 2013; 260: 2614-2619
        • Fragoso YD
        • Elso FG
        • Carrá A
        Differential diagnosis of multiple sclerosis in Latin America.
        Mult. Scler. J. Exp. Transl. Clin. 2017; 3 (Sep 25)2055217317714279
        • Fragoso YD
        • Sousa NAC
        • Alves-Leon SV
        • et al.
        Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD).
        Mult. Scler. Relat. Disord. 2019; 27: 392-396
        • Fryer JP
        • Lennon VA
        • Pittock SJ
        • et al.
        AQP4 autoantibody assay performance in clinical laboratory service.
        Neurol. Neuroimmunol. Neuroinflamm. 2014; 1 (May 22): e11
        • Fujihara K
        • Sato DK
        AQP4 antibody serostatus: is its luster being lost in the management and pathogenesis of NMO?.
        Neurology. 2013; 81: 1186-1188
        • Gaitán MI
        • Yañez P
        • Paday Formenti ME
        • et al.
        SWAN-venule: an optimized MRI technique to detect the central vein sign in MS plaques.
        AJNR Am. J. Neuroradiol. 2020; 41: 456-460
        • Gao F
        • Chai B
        • Gu C
        • Wu R
        • Dong T
        • Yao Y
        • Zhang Y
        Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.
        BMC Neurol. 2019; 19 (Mar 6;): 36
        • Geraldes R
        • Ciccarelli O
        • Barkhof F
        • et al.
        The current role of MRI in differentiating multiple sclerosis from its imaging mimics [published correction appears in Nat Rev Neurol. 2018 Mar 20;14 (4):213].
        Nat. Rev. Neurol. 2018; 14: 199-213
        • Ghezzi A
        • Bergamaschi R
        • Martinelli V
        • et al.
        Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica.
        J. Neurol. 2004; 251 (Jan): 47-52
        • Gray D.J.
        • Ross A.G.
        • Li Y.-S.
        • McManus D.P.
        Diagnosis and management of schistosomiasis.
        BMJ. 2011; 342: d2651
        • Hamid S.H.
        • Elsone L.
        • Mutch K.
        • et al.
        The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.
        Mult. Scler. 2017; 23: 228-233
        • Hamid SHM
        • Whittam D
        • Mutch K
        • et al.
        What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.
        J. Neurol. 2017; 264: 2088-2094
        • Hor JY
        • Asgari N
        • Nakashima I
        • et al.
        Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide.
        Front. Neurol. 2020; 11: 501
        • Hu H
        • You X
        • Ye J
        Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders.
        Mult. Scler. Relat. Disord. 2018; 21: 78-83
        • Huang Q
        • Wang J
        • Zhou Y
        • Yang H
        • Wang Z
        • Yan Z
        • Long Y
        • Yin J
        • Feng H
        • Li C
        • Lu Z
        • Hu X
        • Qiu W
        Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in South China.
        Front. Immunol. 2018; 9 (Sep 11): 2066
        • Huang W
        • Wang L
        • Zhang B
        • Zhou L
        • Zhang T
        • Quan C
        Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis.
        Mult. Scler. Relat. Disord. 2019; 35 (Oct;): 246-252
        • Huang Y
        • Wang Y
        • Zhou Y
        • et al.
        Pregnancy in neuromyelitis optica spectrum disorder: a multicenter study from South China.
        J. Neurol. Sci. 2017; 372: 152-156
        • Huh SY
        • Kim SH
        • Hyun JW
        • et al.
        Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
        JAMA Neurol. 2014; 71: 1372-1378
        • Huh SY
        • Kim SH
        • Hyun JW
        • Jeong IH
        • Park MS
        • Lee SH
        • et al.
        Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders.
        Mult. Scler. 2017; 23: 413-419
        • Hyun J.W.
        • Jeong I.H.
        • Joung A.
        • et al.
        Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder.
        Neurology. 2016; 86: 1772-1779
        • Hyun JW
        • Jang H
        • Yu J
        • Park NY
        • Kim SH
        • Huh SY
        • Kim W
        • Park MS
        • Oh J
        • Park KD
        • Kim HJ
        Comparison of neuropathic pain in neuromyelitis optica spectrum disorder and multiple sclerosis.
        J. Clin. Neurol. 2020; 16: 124-130
        • Jacob A
        • Matiello M
        • Weinshenker BG
        • et al.
        Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
        Arch. Neurol. 2009; 66: 1128-1133
        • Jacob A
        • Weinshenker BG
        • Violich I
        • et al.
        Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
        Arch. Neurol. 2008; 65: 1443-1448
        • Jarius S
        • Aboul-Enein F
        • Waters P
        • et al.
        Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
        Brain. 2008; 131: 3072-3080
        • Jarius S
        • Franciotta D
        • Paul F
        • et al.
        Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance.
        J. Neuroinflammation. 2010; 7: 52
        • Jarius S
        • Paul F
        • Aktas O
        • et al.
        MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.
        J. Neuroinflammation. 2018; 15: 134
        • Jarius S
        • Paul F
        • Franciotta D
        • et al.
        Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
        J. Neurol. Sci. 2011; 306 (Jul 15): 82-90
        • Jarius S
        • Ruprecht K
        • Wildemann B
        • et al.
        Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients.
        J. Neuroinflammation. 2012; 9: 14
        • Jarius S
        • Wildemann B
        Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature.
        Brain Pathol. 2013; 23: 661-683
        • Jarius S.
        • et al.
        MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
        J. Neuroinflammation. 2016; 13: 279
        • Jeong IH
        • Park B
        • Kim SH
        • Hyun JW
        • Joo J
        • Kim HJ
        Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints.
        Mult. Scler. 2016; 22: 329-339
        • Juryńczyk M
        • Jacob A
        • Fujihara K
        • Palace J
        Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations.
        Pract Neurol. 2019; 19: 187-195
        • Kawachi I
        • Lassmann H.
        Neurodegeneration in multiple sclerosis and neuromyelitis optica.
        J. Neurol. Neurosurg. Psychiatry. 2017; 88: 137-145
        • Kim HJ
        • Paul F
        • Lana-Peixoto MA
        • et al.
        MRI characteristics of neuromyelitis optica spectrum disorder: an international update.
        Neurology. 2015; 84: 1165-1173
        • Kim S.H.
        • Kim W.
        • Li X.F.
        • et al.
        Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
        Arch. Neurol. 2011; 68: 1412-1420
        • Kim SH
        • Hyun JW
        • Joung A
        • Lee SH
        • Kim HJ
        Occurrence of asymptomatic acute neuromyelitis optica spectrum disorder-typical brain lesions during an attack of optic neuritis or myelitis.
        PLoS ONE. 2016; 11e0167783
        • Kim SH
        • Hyun JW
        • Joung A
        • Park EY
        • Joo J
        • Kim HJ
        Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.
        Mult. Scler. 2017; 23: 1902-1908
        • Kim SH
        • Hyun JW
        • Kim HJ
        Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder.
        Neurochem. Int. 2019; 130 (Nov;)104347
        • Kim SH
        • Jeong IH
        • Hyun JW
        • et al.
        Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab.
        JAMA Neurol. 2015; 72: 989-995
        • Kim SM
        • Kim SJ
        • Lee HJ
        • Kuroda H
        • Palace J
        • Fujihara K
        Differential diagnosis of neuromyelitis optica spectrum disorders.
        Ther. Adv. Neurol. Disord. 2017; 10: 265-289
        • Kim SM
        • Park J
        • Kim SH
        • et al.
        Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
        PLoS ONE. 2013; 8: e82325
        • Kim SM
        • Waters P
        • Vincent A
        • et al.
        Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica.
        J. Neurol. 2011; 258: 2176-2180
        • Kim W
        • Kim SH
        • Nakashima I
        • et al.
        Influence of pregnancy on neuromyelitis optica spectrum disorder.
        Neurology. 2012; 78: 1264-1267
        • Kim YJ
        • Jung SW
        • Kim Y
        • et al.
        Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: comparison of tissue-based and cell-based indirect immunofluorescence assays and ELISA.
        J. Clin. Lab. Anal. 2012; 26: 184-189
        • Kimbrough DJ
        • Fujihara K
        • Jacob A
        • et al.
        Treatment of neuromyelitis optica: review and recommendations.
        Mult. Scler. Relat. Disord. 2012; 1 (Oct): 180-187
        • Kitley J
        • Leite MI
        Nakashima I et al Prognostic factors and disease course in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
        Brain. 2012; 135: 1834-1849
        • Klawiter EC
        • Bove R
        • Elsone L
        • Alvarez E
        • Borisow N
        • Cortez M
        • et al.
        High risk of postpartum relapses in neuromyelitis optica spectrum disorder.
        Neurology. 2017; 89: 2238-2244
        • Kleiter I
        • Gahlen A
        • Borisow N
        • Fischer K
        • Wernecke KD
        • Hellwig K
        • et al.
        Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions.
        Neurol. Neuroimmunol. Neuroinflamm.. 2018; 5: e504
        • Kleiter I
        • Gahlen A
        • Borisow N
        • Fischer K
        • Wernecke KD
        • Wegner B
        • et al.
        Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses.
        Ann. Neurol. 2016; 79: 206-216
        • Lana-Peixoto MA
        • Pedrosa D
        • Talim N
        • Amaral JMSS
        • Horta A
        • Kleinpaul R
        Neuromyelitis optica spectrum disorder associated with dengue virus infection.
        J. Neuroimmunol. 2018; 318 (May 15): 53-55
        • Lana-Peixoto MA
        • Talim N.
        Neuromyelitis optica spectrum disorder and anti-MOG syndromes.
        Biomedicines. 2019; 7
        • Lennon VA
        • Kryzer TJ
        • Pittock SJ
        • et al.
        IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.
        J. Exp. Med. 2005; 202: 473-477
        • Lennon VA
        • Wingerchuk DM
        • Kryzer TJ
        • et al.
        A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
        Lancet. 2004; 364: 2106-2112
        • Li GH
        • Ning ZJ
        • Liu YM
        • Li XH
        Neurological manifestations of dengue infection.
        Front. Cell Infect. Microbiol. 2017; 7: 449
        • Lim YM
        • Pyun SY
        • Kang BH
        • Kim J
        • Kim KK
        Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders.
        Mult. Scler. 2013; 19 (Aug;): 1216-1218
        • Liu J
        • Zhang Q
        • Lian Z
        • Chen H
        • Shi Z
        • Feng H
        • Miao X
        • Du Q
        • Zhou H
        Painful tonic spasm in neuromyelitis optica spectrum disorders: prevalence, clinical implications and treatment options.
        Mult. Scler. Relat. Disord. 2017; 17: 99-102
        • Lotan I
        • Charlson RW
        • Ryerson LZ
        • Levy M
        • Kister I
        Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders.
        Mult. Scler. Relat. Disord. 2019; 39 (Dec 30)101920
        • Magaña SM
        • Keegan BM
        • Weinshenker BG
        • Erickson BJ
        • Pittock SJ
        • Lennon VA
        • Rodriguez M
        • Thomsen K
        • Weigand S
        • Mandrekar J
        • Linbo L
        • Lucchinetti CF
        Beneficial plasma exchange response in central nervous system inflammatory demyelination.
        Arch. Neurol. 2011; 68 (Jul;): 870-878
        • Majed Masoud
        • Fryer James P.
        • McKeon Andrew
        • et al.
        Clinical utility of testing AQP4-IgG in CSF: guidance for physicians.
        Neurol. Neuroimmunol. Neuroinflamm. 2016; 3 (Jun): e231
        • Mandler RN
        • Ahmed W
        • Dencoff JE
        Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine.
        Neurology. 1998; 51: 1219-1220
        • Mao-Draayer Y
        • Thiel S
        • Mills EA
        • Chitnis T
        • Fabian M
        • Katz Sand I
        • Leite MI
        • Jarius S
        • Hellwig K
        Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations.
        Nat Rev Neurol. 2020; (Feb 20)
        • Marcinnò A
        • Marnetto F
        • Valentino P
        • et al.
        Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders.
        Neurol. Neuroimmunol. Neuroinflamm. 2018; 5: e498
        • Marignier R
        • Bernard-Valnet R
        • Giraudon P
        • et al.
        Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity dependent entity.
        Neurology. 2013; 80: 2194-2200
        • Mariotto S
        • Ferrari S
        • Monaco S
        • et al.
        Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody associated syndromes: a multicenter study.
        J. Neurol. 2017; 264: 2420-2430
        • Matiello M
        • Lennon VA
        • Jacob A
        • et al.
        NMO-IgG predicts the outcome of recurrent optic neuritis.
        Neurology. 2008; 70: 2197-2200
        • Matthews LA
        • Marasco R
        • Jenkinson M
        • et al.
        Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.
        Neurology. 2013; 80: 1330-1337
        • McCreary M
        • Mealy MA
        • Wingerchuk DM
        • et al.
        Updated diagnostic criteria for neuromyelitis optica spectrum disorder: similar outcomes of previously separate cohorts.
        Mult. Scler. J. Exp. Transl. Clin. 2018; 4 (Dec 6)2055217318815925
        • McKinney AM
        • Lohman BD
        • Sarikaya B
        • Benson M
        • Lee MS
        • Benson MT
        Accuracy of routine fat-suppressed FLAIR and diffusion-weighted images in detecting clinically evident acute optic neuritis.
        Acta Radiol. 2013; 54: 455-461
        • Mealy MA
        • Kessler RA
        • Rimler Z
        • et al.
        Mortality in neuromyelitis optica is strongly associated with African ancestry.
        Neurol. Neuroimmunol. Neuroinflamm.. 2018; 5 (Published 2018 Jun 7): e468
        • Mealy MA
        • Wingerchuk DM
        • Palace J
        • et al.
        Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
        JAMA Neurol. 2014; 71: 324-330
        • Mok CC
        • To CH
        • Mak A
        • Poon WL
        Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica.
        J. Rheumatol. 2008; 35: 172-174
        • Montcuquet A
        • Collongues N
        • Papeix C
        • Zephir H
        • Audoin B
        • Laplaud D
        • et al.
        Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
        Mult. Scler. 2017; 23: 1377-1384
        • Mutch K
        • Methley A
        • Moore P
        • Jacob A
        Life on hold: the experience of living with neuromyelitis optica.
        Disabil. Rehabil. 2014; 36: 1100-1107
        • Nagaishi A
        • Takagi M
        • Umemura A
        • et al.
        Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes.
        J. Neurol. Neurosurg. Psychiatry. 2011; 82: 1360-1364
        • Nakashima I
        • Takahashi T
        • Cree BA
        • et al.
        Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels.
        J. Clin. Neurosci. 2011; 18: 997-998
        • Narayan R
        • Simpson A
        • Fritsche K
        • et al.
        MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder.
        Mult. Scler. Relat. Disord. 2018; 25: 66-72
        • Nikoo Z
        • Badihian S
        • Shaygannejad V
        • Asgari N
        • Ashtari F
        Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
        J. Neurol. 2017; 264: 2003-2009
        • Nishimura H
        • Enokida H
        • Sakamoto T
        • et al.
        Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level.
        J. Artif. Organs. 2018 Sep; 21: 378-382
        • Nour MM
        • Nakashima I
        • Coutinho E
        • et al.
        Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
        Neurology. 2016; 86: 79-87
        • Oertel FC
        • Zimmermann H
        • Paul F
        • Brandt AU
        Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.
        EPMA J. 2017; 9: 21-33
        • Palace J
        • Leite MI
        • Jacob A
        A practical guide to the treatment of neuromyelitis optica.
        Pract. Neurol. 2012; 12 (Aug): 209-214
        • Palace J
        • Lin DY
        • Zeng D
        • et al.
        Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.
        Brain. 2019; 142: 1310-1323
        • Papais-Alvarenga RM
        • Carellos SC
        • Alvarenga MP
        • Holander C
        • Bichara RP
        • Thuler LC
        Clinical course of optic neuritis in patients with relapsing neuromyelitis optica.
        Arch. Ophthalmol. 2008; 126 (Jan): 12-16
        • Papais-Alvarenga RM
        • Neri VC
        • de Araújo E
        • Araújo ACR
        • et al.
        Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: an ethnicity influence?.
        Mult. Scler. Relat. Disord. 2018; 25: 87-94
        • Papais-Alvarenga RM
        • Vasconcelos CC
        • Carra A
        • et al.
        Central nervous system idiopathic inflammatory demyelinating disorders in South Americans: a descriptive, multicenter, cross-sectional study.
        PLoS ONE. 2015; 10 (Jul 29)e0127757
        • Papais-Alvarenga RM
        • Vasconcelos CC
        • Carra A
        • et al.
        Central nervous system idiopathic inflammatory demyelinating disorders in South Americans: a descriptive, multicenter, cross-sectional study.
        PLoS ONE. 2015; 10e0127757
        • Pellkofer HL
        • Krumbholz M
        • Berthele A
        • et al.
        Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
        Neurology. 2011; 76: 1310-1315
        • Perumal J.S.
        • Kister I.
        • Howard J.
        • Herbert J.
        Disease exacerbation after rituximab induction in neuromyelitis optica.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e61
        • Petzold A
        • Wattjes MP
        • Costello F
        • et al.
        The investigation of acute optic neuritis: a review and proposed protocol [published correction appears in Nat Rev Neurol. 2014 Aug;10(8):i].
        Nat Rev Neurol. 2014; 10: 447-458
        • Pittock SJ
        • Berthele A
        • Fujihara K
        • et al.
        Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
        N. Engl. J. Med. 2019; 381 (Aug 15): 614-625
        • Pittock SJ
        • Lennon VA
        • de Seze J
        • et al.
        Neuromyelitis optica and non-organ-specific autoimmunity.
        Arch. Neurol. 2008; 65: 78-83
        • Pittock SJ
        • Lennon VA
        • Krecke K
        • Wingerchuk DM
        • Lucchinetti CF
        • Weinshenker BG
        Brain abnormalities in neuromyelitis optica.
        Arch. Neurol. 2006; 63: 390-396
        • Prain Kerri
        • Woodhall Mark
        • Vincent Angela
        • Brilot Fabienne
        • Waters Patrick
        • Broadley Simon A.
        • et al.
        • The Australian and New Zealand NMO Collaboration
        • The Australian and New Zealand NMO Collaboration
        AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD.
        Front. Neurol. 2019; 10: 1028
        • Qiu W
        • Kermode AG
        • Li R
        • et al.
        Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica.
        J. Clin. Neurosci. 2015; 22: 1178-1182
      1. Rand Corporation. The RAND/UCLA appropriateness method user's manual. Santa Monica: RAND; 2001. Development of Good Practice Guidelines. ‘‘Formal Consensus’’ Method. December 2010, updated March2015.https://www.hassante.fr/portail/upload/docs/application/pdf/201803/good_practice_guidelines_fc_method.pdf.

        • Reindl M
        • Schanda K
        • Woodhall M
        • et al.
        International multicenter examination of MOG antibody assays.
        Neurol. Neuroimmunol. Neuroinflamm. 2020; 7 (Feb 5)
        • Reindl M
        • Waters P.
        Myelin oligodendrocyte glycoprotein antibodies in neurological disease.
        Nat. Rev. Neurol. 2019; 15: 89-102
        • Ringelstein M
        • Ayzenberg I
        • Harmel J
        • et al.
        Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder.
        JAMA Neurol. 2015; 72: 756-763
        • Rivas-Alonso V
        • Flores-Rivera JDJ
        • Rito-García Y
        • et al.
        Neuromyelitis optica (NMO IgG+) and genetic susceptibility, potential ethnic influences.
        Cent. Nerv. Syst. Agents Med. Chem. 2018; 18 (Jan 26;): 4-7
        • Rivera JF
        • Kurtzke JF
        • Booth VJ
        • Corona T
        Characteristics of devic's disease (neuromyelitis optica) in Mexico.
        J Neurol. 2008; 255 (2): 710-715
        • Salvador NRS
        • Brito MNG
        • Alvarenga MP
        • Alvarenga RMP
        Neuromyelitis optica and pregnancy-puerperal cycle.
        Mult. Scler. Relat. Disord. 2019; 34 (Sep): 59-62
        • Santori G
        • Fontana I
        • Valente R
        • Ghirelli R
        • Valente U
        Application of the RAND/UCLA appropriateness method to evaluate an information system for kidney/pancreas transplantation in adult recipients.
        Transplant. Proc. 2008; 40: 2021-2023
        • Sati P
        • Oh J
        • Constable RT
        • et al.
        The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.
        Nat. Rev. Neurol. 2016; 12: 714-722
        • Sato DK
        • Callegaro D
        • Lana-Peixoto MA
        • et al.
        Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
        Neurology. 2014; 82: 474-481
        • Sato DK
        • Callegaro D
        • Lana-Peixoto MA
        • et al.
        Seronegative neuromyelitis optica spectrum—the challenges on disease definition and pathogenesis.
        Arq. Neuropsiquiatr. 2014; 72: 445-450
        • Sellner J
        • Boggild M
        • Clanet M
        • Hintzen RQ
        • Illes Z
        • Montalban X
        • Du Pasquier RA
        • Polman CH
        • Sorensen PS
        • Hemmer B
        EFNS guidelines on diagnosis and management of neuromyelitis optica.
        Eur. J. Neurol. 2010; 17: 1019-1032
        • Seok JM
        • Cho EB
        • Lee HL
        • et al.
        Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder.
        J. Neurol. Sci. 2016; 368 (Sep 15): 209-213
        • Seze Jerome De
        • Weinshenker Brian G.
        • Terada Yusuke
        Efficacy and safety of satralizumab for relapse prevention in neuromyelitis optica spectrum disorder: a pooled analysis from two phase 3 clinical trials.
        Mult. Scler. 2020; 37 (January 01)101592https://doi.org/10.1016/j.msard.2019.11.067
        • Shaygannejad V
        • Fayyazi E
        • Badihian S
        • et al.
        Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.
        J. Neurol. 2019; 266: 642-650
        • Shi Z
        • Du Q
        • Chen H
        • et al.
        Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study.
        J. Neurol. 2019; (Nov 27[Epub ahead of print])https://doi.org/10.1007/s00415-019-09649-7
        • Shimizu Y
        • Fujihara K
        • Ohashi T
        • Nakashima I
        • Yokoyama K
        • Ikeguch R
        • et al.
        Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder.
        Mult. Scler. 2016; 22: 1413-1420
        • Shosha E
        • Pittock SJ
        • Flanagan E
        • Weinshenker BG
        Neuromyelitis optica spectrum disorders and pregnancy: interactions and management.
        Mult. Scler. 2017; 23: 1808-1817
        • Silveira F
        • Pappolla A
        • Sánchez F
        • et al.
        Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population.
        Mult. Scler. Relat. Disord. 2020; 42102049
        • Sinnecker T
        • Clarke MA
        • Meier D
        • et al.
        Evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis [published online ahead of print, 2019 Aug 19].
        JAMA Neurol. 2019; 76https://doi.org/10.1001/jamaneurol.2019.2478
        • Songthammawat T
        • Srisupa-Olan T
        • Siritho S
        • et al.
        A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX.
        Mult. Scler. Relat. Disord. 2019; 38 (Nov 6)101506
        • Sotirchos ES
        • Filippatou A
        • Fitzgerald KC
        • et al.
        Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning [published online ahead of print, 2019 Jul 31].
        Mult. Scler. 2019; (1352458519864928)
        • Soto de Castillo I
        • Molina O
        • Soto A
        • et al.
        Neuromyelitis optica spectrum disorders: epidemiologic study in Venezuela.
        in: Presented at the 11th International NMO Roundtable Conference, Los Angeles2019
        • Srikajon J
        • Siritho S
        • Ngamsombat C
        • Prayoonwiwat N
        • Chirapapaisan N
        • Siriraj Neuroimmunology Research Group
        Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis.
        Mult. Scler. J. Exp. Transl. Clin. 2018; 4 (Aug 11;)2055217318791196
        • Stellmann JP
        • Krumbholz M
        • Friede T
        • Gahlen A
        • Borisow N
        • Fischer K
        • et al.
        Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.
        J. Neurol. Neurosurg. Psychiatry. 2017; 88: 639-647
        • Stiebel-Kalish H
        • Hellmann MA
        • Mimouni M
        • et al.
        Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?.
        Neurol. Neuroimmunol. Neuroinflamm.. 2019; 6 (Published 2019 May 21): e572
        • Takahashi T
        • Fujihara K
        • Nakashima I
        • et al.
        Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.
        Brain. 2007; 130: 1235-1243
        • Thompson AJ
        • Banwell BL
        • Barkhof F
        • et al.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        Lancet Neurol. 2018; 17: 162-173
        • Torres J
        • Pruitt A
        • Balcer L
        • et al.
        Analysis of the treatment of neuromyelitis optica.
        J. Neurol. Sci. 2015; 351: 31-35
        • Trebst C
        • Jarius S
        • Berthele A
        • Neuromyelitis Optica Study Group (NEMOS)
        • et al.
        Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).
        J. Neurol. 2014; 261: 1-16
        • von Glehn F
        • Jarius S
        • Penalva de Oliveira AC
        • et al.
        Aquaporin-4 antibodies are not related to HTLV-1 associated myelopathy.
        PLoS ONE. 2012; 7: e39372
        • Watanabe S
        • Misu T
        • Miyazawa I
        • Nakashima I
        • Shiga Y
        • Fujihara K
        • et al.
        Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis.
        Mult. Scler. 2007; 13: 968-974
        • Waters P
        • McKeon A
        • Leite M
        • et al.
        Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.
        Neurology. 2012; 78: 665-671
        • Waters P
        • Woodhall M
        • O’Connor KC
        • et al.
        MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e89
        • Waters PJ
        • Pittock SJ
        • Bennett JL
        • Jarius S
        • Weinshenker BG
        • Wingerchuk DM
        Evaluation of aquaporin-4 antibody assays.
        Clin. Exp. Neuroimmunol. 2014; 5: 290-303
        • Weinshenker BG
        • O'Brien PC
        • Petterson TM
        • Noseworthy JH
        • Lucchinetti CF
        • Dodick DW
        • et al.
        A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.
        Ann. Neurol. 1999; 46: 878-886
        • Weinshenker BG
        • Wingerchuk DM
        • Vukusic S
        • et al.
        Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.
        Ann. Neurol. 2006; 59: 566-569
        • Weinshenker BG
        • Wingerchuk DM.
        Neuromyelitis spectrum disorders.
        Mayo Clin. Proc. 2017; 92: 663-679
        • Weinstock-Guttman B
        • Ramanathan M
        • Lincoff N
        • Napoli SQ
        • Sharma J
        • Feichter J
        • et al.
        Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
        Arch. Neurol. 2006; 63: 957-963
        • Whittam D
        • Wilson M
        • Hamid S
        • Keir G
        • Bhojak M
        • Jacob A
        What's new in neuromyelitis optica? A short review for the clinical neurologist.
        J. Neurol. 2017; 264: 2330-2344
        • Wingerchuk D
        • Lennon V
        • Lucchinetti C
        • et al.
        The spectrum of neuromyelitis optica.
        Lancet Neurol. 2007; 6: 805-815
        • Wingerchuk D
        • Weinshenker B
        The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease.
        Mult. Scler. 2012; 18: 5-10
        • Wingerchuk D.M.
        • Pittock S.J.
        • Lucchinetti C.F.
        • et al.
        A secondary progressive clinical course is uncommon in neuromyelitis optica.
        Neurology. 2007; 68: 603-605
        • Wingerchuk D.M.
        • Weinshenker B.G.Neuromyelitis optica:
        clinical predictors of a relapsing course and survival.
        Neurology. 2003; 60: 848-853
        • Wingerchuk DM
        • Banwell B
        • Bennett JL
        • International Panel for NMO Diagnosis
        • et al.
        International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
        Neurology. 2015; 85: 177-189
        • Wingerchuk DM
        • Hogancamp WF
        • O'Brien PC
        • et al.
        The clinical course of neuromyelitis optica (Devic's syndrome).
        Neurology. 1999; 53: 1107-1114
        • Wingerchuk DM
        • Lennon VA
        • Pittock SJ
        • Lucchinetti CF
        • Weinshenker BG
        Revised diagnostic criteria for neuromyelitis optica.
        Neurology. 2006; 66: 1485-1489
        • Yamamura T
        • Kleiter I
        • Fujihara K
        • Palace J
        • Greenberg B
        • Zakrzewska-Pniewska B
        • Patti F
        • Tsai CP
        • Saiz A
        • Yamazaki H
        • Kawata Y
        • Wright P
        • De Seze J
        Trial of satralizumab in neuromyelitis optica spectrum disorder.
        N. Engl. J. Med. 2019; 381 (Nov 28;): 2114-2124
        • Yang Y
        • Wang CJ
        • Wang BJ
        • Zeng ZL
        • Guo SG
        Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
        J. Neurol. Sci. 2018; 385: 192-197
        • Zamvil SS
        • Slavin AJ.
        Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?.
        Neurol. Neuroimmunol. Neuroinflamm. 2015; 2: e62
        • Zatjirua V
        • Butler J
        • Carr J
        • et al.
        Neuromyelitis optica and pulmonary tuberculosis: a case-control study.
        Int. J. Tuberc. Lung Dis. 2011; 15: 1675-1680
        • Zephir H
        • Bernard-Valnet R
        • Lebrun C
        • et al.
        Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
        J. Neurol. 2015; 262: 2329-2335
        • Zhang C
        • Zhang M
        • Qiu W
        • et al.
        Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
        Lancet Neurol. 2020; 19: 391-401

      Linked Article